VHH Molecules Transferrin Receptor Binding CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) poses a significant obstacle to drug delivery for central nervous system (CNS) disorders, as it is impermeable to most molecules, including therapeutic peptides and proteins, limiting the effectiveness of treatments for CNS pathologies.
Innovation Solution
Development of Variable Domain of Camelid Heavy Chain-only (VHH) molecules that bind to the transferrin receptor (TfR) on the BBB, allowing for the transport of therapeutic and diagnostic agents across the BBB through receptor-mediated transcytosis, with affinity for both human and non-human TfR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the BBB is made impermeable to protect the brain from toxins and pathogens, then protection efficiency is improved, but drug delivery capability deteriorates
Solution Approach 1:
The patent uses transferrin receptor-binding molecules as intermediary carriers that exploit the existing TfR-mediated transcytosis pathway. These molecules bind to TfR on the luminal side of BBB endothelial cells, are internalized via receptor-mediated endocytosis, transported across the cell, and released on the abluminal side, thereby mediating drug delivery through the barrier without compromising its protective function
Solution Approach 2:
The invention leverages the BBB's own physiological transport mechanism (TfR-mediated transcytosis) to deliver therapeutic agents. By conjugating drugs to TfR-binding molecules, the system utilizes the brain's natural iron transport pathway for self-service drug delivery, turning the barrier's selective permeability into a delivery advantage rather than an obstacle
2Adaptability or versatility
If only small lipophilic molecules are allowed to pass through the BBB, then barrier selectivity is improved, but therapeutic peptide and protein delivery deteriorates
Solution Approach 1:
The patent changes the key parameter of molecular size and polarity requirements for BBB penetration. By using TfR-binding molecules as carriers, large hydrophilic therapeutic peptides and proteins can be delivered through the BBB via receptor-mediated transcytosis, bypassing the size and lipophilicity constraints that limit passive diffusion
Solution Approach 2:
TfR-binding molecules serve as intermediary carriers that enable therapeutic peptides and proteins to cross the BBB. These carriers bind to the transferrin receptor, facilitate transport across the endothelial cell, and release the therapeutic cargo on the brain side, thereby mediating the passage of molecules that would otherwise be excluded by the barrier
3Productivity
If direct injection into the CNS is used to avoid the BBB, then drug delivery effectiveness is improved, but invasiveness and risk deteriorates
Solution Approach 1:
The patent uses TfR-binding molecules as intermediaries to transport drugs across the intact BBB from the bloodstream into the brain. This approach maintains the BBB's protective barrier function while enabling effective drug delivery to the CNS, avoiding the need for invasive procedures such as direct brain injection or ventricular catheterization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
VHH molecules effectively transmigrate through the CNS, delivering conjugated drugs or imaging agents in vivo, providing a valuable approach for therapeutic and diagnostic applications by overcoming the BBB barrier.
Implementation Method 1
bind to the transferrin receptor (TfR) on the BBB, allowing for the transport of therapeutic and diagnostic agents across the BBB through receptor-mediated transcytosis
Data Source
AI summary
The invention relates to Variable Domain of Camelid Heavy Chain-only (VHH) molecules which bind TfR and the uses thereof e.g., to transport molecules of pharmaceutical or diagnostic interest into cells and in organs, in pathological conditions including cancer.